AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
-0.1%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$210M
AUM Growth
+$210M
(+2.9%)
Cap. Flow
+$13.3M
Cap. Flow
% of AUM
6.34%
Top 10 Holdings %
Top 10 Hldgs %
53.68%
Holding
85
New
10
Increased
25
Reduced
14
Closed
11
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$4.04M |
| 2 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
$3.84M |
| 3 |
Zentalis Pharmaceuticals
ZNTL
|
$3.45M |
| 4 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$3.26M |
| 5 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$2.94M |
Top Sells
| 1 |
Travere Therapeutics
TVTX
|
$5.49M |
| 2 |
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
|
$2.96M |
| 3 |
Curis
CRIS
|
$2.82M |
| 4 |
Celldex Therapeutics
CLDX
|
$2.68M |
| 5 |
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
|
$2.5M |
Sector Composition
| 1 | Healthcare | 90.08% |
| 2 | Financials | 4.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BridgeBio Pharma
BBIO
$9.89B
| $33.5M | 12% | 550,000 -27,500 | -5% | -$1.68M |
|
|
MORF
2
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $14.1M | 5.06% | 246,201 +51,201 | +26% | +$2.94M |
|
|
VINC
3
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $10.9M | 3.9% | 838,311 +295,301 | +54% | +$3.84M |
|
4
Nautilus Biotechnolgy
NAUT
$85.9M
| $9.09M | 3.25% | 900,000 +211,000 | +31% | +$2.13M |
|
5
Kura Oncology
KURA
$686M
| $8.86M | 3.17% | 425,000 +60,000 | +16% | +$1.25M |
|
|
NARI
6
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $7.93M | 2.84% | 85,000 +35,000 | +70% | +$3.26M |
|
|
7
Zentalis Pharmaceuticals
ZNTL
$122M
| $7.58M | 2.71% | 142,418 +64,918 | +84% | +$3.45M |
|
|
ARYD
8
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $7.5M | 2.69% | 700,000 | – | – |
|
|
XLRN
9
DELISTED
Acceleron Pharma Inc.
XLRN
| $6.9M | 2.47% | 55,000 +10,000 | +22% | +$1.25M |
|
|
10
Protagonist Therapeutics
PTGX
$3.67B
| $6.29M | 2.25% | 140,100 +90,100 | +180% | +$4.04M |
|
11
Rocket Pharmaceuticals
RCKT
$354M
| $5.32M | 1.9% | 120,000 +35,000 | +41% | +$1.55M |
|
|
12
Curis
CRIS
$20.9M
| $5.25M | 1.88% | 650,000 -350,000 | -35% | -$2.82M |
|
|
CERE
13
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $5.12M | 1.83% | 200,000 -70,000 | -26% | -$1.79M |
|
14
Aclaris Therapeutics
ACRS
$209M
| $4.83M | 1.73% | 275,000 +52,733 | +24% | +$926K |
|
15
Ocular Therapeutix
OCUL
$2.12B
| $3.55M | 1.27% | 250,000 +22,500 | +10% | +$319K |
|
16
Orchestra BioMed
OBIO
$147M
| $3.06M | 1.1% | 300,000 +75,000 | +33% | +$765K |
|
|
MSAC
17
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| $2.9M | 1.04% | +300,000 | New | +$2.9M |
|
|
KDNY
18
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $2.82M | 1.01% | 200,000 +25,000 | +14% | +$353K |
|
19
Pulmonx
LUNG
$69.7M
| $2.65M | 0.95% | 60,000 +15,000 | +33% | +$662K |
|
20
Ascendis Pharma
ASND
$11.8B
| $2.63M | 0.94% | 20,000 | – | – |
|
21
Iovance Biotherapeutics
IOVA
$807M
| $2.6M | 0.93% | 100,000 +75,400 | +307% | +$1.96M |
|
|
HZNP
22
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.34M | 0.84% | 25,000 -10,000 | -29% | -$936K |
|
23
Aldeyra Therapeutics
ALDX
$351M
| $2.27M | 0.81% | 200,000 -100,000 | -33% | -$1.13M |
|
24
Cyclacel Pharmaceuticals
CYCC
$18.4M
| $2.25M | 0.81% | 380,000 | – | – |
|
25
MacroGenics
MGNX
$112M
| $2.15M | 0.77% | 80,000 +55,000 | +220% | +$1.48M |
|